Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge

Open access
Cavallaro, Giacomo, Filippi, Luca, Bagnoli, Paola, La Marca, Giancarlo, Cristofori, Gloria, Raffaeli, Genny, Padrini, Letizia, Araimo, Gabriella, Fumagalli, Monica, Groppo, Michela, Dal Monte, Massimo, Osnaghi, Silvia, Fiorini, Patrizio, Mosca, Fabio · 2014 · Acta Ophthalmologica

Abstract

: Retinopathy of prematurity (ROP) is a disease that can cause blindness in very low birthweight infants. The incidence of ROP is closely correlated with the weight and the gestational age at birth. Despite current therapies, ROP continues to be a highly debilitating disease. Our advancing knowledge of the pathogenesis of ROP has encouraged investigations into new antivasculogenic therapies. The purpose of this article is to review the findings on the pathophysiological mechanisms that contribute to the transition between the first and second phases of ROP and to investigate new potential therapies. Oxygen has been well characterized for the key role that it plays in retinal neoangiogenesis. Low or high levels of pO 2 regulate the normal or abnormal production of hypoxia‐inducible factor 1 and vascular endothelial growth factors (VEGF), which are the predominant regulators of retinal angiogenesis. Although low oxygen saturation appears to reduce the risk of severe ROP when carefully controlled within the first few weeks of life, the optimal level of saturation still remains uncertain. IGF‐1 and Epo are fundamentally required during both phases of ROP, as alterations in their protein levels can modulate disease progression. Therefore, rhIGF‐1 and rhEpo were tested for their abilities to prevent the loss of vasculature during the first phase of ROP, whereas anti‐VEGF drugs were tested during the second phase. At present, previous hypotheses concerning ROP should be amended with new pathogenetic theories. Studies on the role of genetic components, nitric oxide, adenosine, apelin and β‐adrenergic receptor have revealed new possibilities for the treatment of ROP. The genetic hypothesis that single‐nucleotide polymorphisms within the β‐ARs play an active role in the pathogenesis of ROP suggests the concept of disease prevention using β‐blockers. In conclusion, all factors that can mediate the progression from the avascular to the proliferative phase might have significant implications for the further understanding and treatment of ROP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/aos.12049

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 193

Metadata

Authors
Cavallaro, G., Filippi, L., Bagnoli, P., La Marca, G., Cristofori, G., Raffaeli, G., Padrini, L., Araimo, G., Fumagalli, M., Groppo, M., Dal Monte, M., Osnaghi, S., Fiorini, P., & Mosca, F.
Venue
Acta Ophthalmologica
Publisher
Wiley
Published
2013-04-26
Volume
92
Issue
1
Pages
2-20
ISSN
  • 0001-639X (ISSN-L)
  • 1755-375X
  • 1755-3768
OpenAlex
W2002330978
Cited by
193
References
6
FWCI
9.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. https://app.cochat.ai/papers/10.1111/aos.12049
The paper
Cavallaro, G., Filippi, L., Bagnoli, P., La Marca, G., Cristofori, G., Raffaeli, G., Padrini, L., Araimo, G., Fumagalli, M., Groppo, M., Dal Monte, M., Osnaghi, S., Fiorini, P., & Mosca, F. (2014). The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. Acta Ophthalmologica. https://doi.org/10.1111/aos.12049

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.